Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06883097 · ClinicalTrials.gov registry record · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
A NA study of Smoking Cessation and Human Immunodeficiency Virus (HIV), sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 314
- Enrollment target
- 1
- Study location
NCT06883097: Recruiting NA study of Smoking Cessation and Human Immunodeficiency Virus (HIV), sponsored by Wake Forest University Health Sciences.
NCT06883097 is a NA study of Smoking Cessation and Human Immunodeficiency Virus (HIV) that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 314 participants, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06883097, a NA study of Smoking Cessation and Human Immunodeficiency Virus (HIV), is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 314 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, they will also receive a combination of nicotine replacement therapy (patches and gums) that have been shown to help people quit smoking. The main questions this study aims to answer are: Participants will complete 5 video call visits over about 6 months. Participants will install their assigned smoking cessation app onto their phone and will be asked to use the app for the duration of the study along with their provided Nicotine Replacement Therapy (NRT) products. During the study visits, participants will meet with study staff to complete questionnaires and interviews. Participants may be asked to provide breath and saliva samples to measure the level of carbon monoxide and nicotine.
Primary Outcome
Abstinence is determined by a self-report of not smoking any cigarettes for greater than or equal to 7 days prior to Weeks 6, 12, 18, and 24 and biochemically verified by an expired carbon monoxide breath test or a cotinine level saliva test at Weeks 6, 12, 18, and 24. Criteria for the bioverification tests to be considered abstinent includes a reading of \<6 parts per million using an iCOquit Smokerlyzer carbon monoxide breath test OR a cotinine level of 30 or less ng/ml using an iScreen saliva
Conditions Studied
Interventions
- BEHAVIORAL Learn to Quit-HIV (LTQ-H) App
- BEHAVIORAL QuitStart
Study Locations (1)
North Carolina
- Wake Forest University, Implementation Science - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT06883097 shows while recruiting
NCT06883097 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (34% lower).
The record links to 7 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Learn to Quit-HIV (LTQ-H) App is the first listed.
NCT06883097 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06883097 about?
NCT06883097 is a clinical study titled "Quitting Matters Human Immunodeficiency Virus Hybrid Trial". The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smok...
What is the current status of trial NCT06883097?
This trial is currently recruiting. It is a NA study. The enrollment target is 314 participants. The study started on 2025-08-18. Estimated completion is 2028-12.
What conditions does trial NCT06883097 study?
This clinical trial studies the following conditions: Smoking Cessation, Human Immunodeficiency Virus (HIV), Cancer Prevention, Tobacco, Smoking Cessation; Tobacco Dependence.
What interventions are being tested in trial NCT06883097?
The interventions under investigation include: Learn to Quit-HIV (LTQ-H) App (BEHAVIORAL), QuitStart (BEHAVIORAL).
Who is sponsoring clinical trial NCT06883097?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06883097 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06883097's enrollment target sits among peer trials
314 76th of 188 higher than 113 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
RECRUITING · NA
-
Urban and Reservation Implementation of All Nations Breath of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT07054073 · 314 participants
HCMR Re-Imaging Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI